drugset / Trial / NCT05007938
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Phase 2
Active not recruiting
30 enrolled
Betta Pharmaceuticals Co., Ltd.
The First Affiliated Hospital of Xiamen University · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
Timeline
- Start
- 2021-08-12
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Befotertinib | Small molecule | 25 mg | Oral |
| Subject | Icotinib | Small molecule | 125 mg | Oral |